TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01129674
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
Study: NCT00428129
Drug: microplasmin
Normalized name: Microplasmin
DrugBank: Ocriplasmin (DB08888)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
Study: NCT01225887
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02869438
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Study: NCT02361944
Drug: Oxygen - normoxia
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
Study: NCT02361944
Drug: Oxygen - hyperoxia
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
Study: NCT00120861
Drug: valopicitabine
Normalized name: Valtorcitabine
DrugBank: Valopicitabine (DB13920)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00120861
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00120861
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02879227
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f
Study: NCT02879227
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
Study: NCT00658580
Drug: Cisplatin + etoposide
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks
Study: NCT00658580
Drug: Epirubicin + ifosfamide + etoposide
Normalized name: Etoposide
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks
Study: NCT02439879
Drug: Alpha lipoic acid
Normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased \>3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
Study: NCT03387683
Drug: dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dapagliflozin 10mg
Study: NCT01368432
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
Study: NCT04190654
Drug: KW-6356
Normalized name: KW-7158
DrugBank: KW-6356 (DB17080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of KW-6356
Study: NCT00810524
Drug: lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study: NCT00810524
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study: NCT00810524
Drug: Enticavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
Study: NCT00810524
Drug: Adefovir Dipivoxil Tablets
Normalized name: Adefovir Dipivoxil Tablets
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
Study: NCT02738632
Drug: Telmisartan/Amlodipine
Normalized name: telmisartan/amlodipine 40 mg-5 mg ORAL TABLET
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD
Study: NCT01008150
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01008150
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01008150
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000188
Drug: Selegiline
Normalized name: Selegiline
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02089854
Drug: Toremifene; Anastrozole
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
Study: NCT02119091
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01916967
Drug: Desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
Study: NCT04375618
Drug: RhEGF
Normalized name: Hu-rhEGF-rP64k/Mont
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The EGF impregnated membrane will be placed upon the recession site and will be stabilized by suturing it to the lingual papillae using 4-0 absorbable sutures. The flap will be coronally advanced as far as possible to cover the membrane and will be sutured to the buccal interdental papillae with 4-0 absorbable sutures (Trulenetm, Healthium Medtech Pvt Ltd, Bangalore, India). Standard recall and maintenance regimen will be followed and subjects will be encouraged to report to the department on a monthly basis.
Study: NCT00846287
Drug: Hyperpolarized Helium-3
Normalized name: Helium
DrugBank: Helium (DB09155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
Study: NCT00846287
Drug: Aformoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive the drug arformoterol prior to scanning
Study: NCT04447378
Drug: Fondaparinux 2.5Mg/0.5Ml Inj Syr
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: post natal thromboprophylaxis
Study: NCT01271114
Drug: Hypertonic Saline and Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
Study: NCT01536691
Drug: ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
Study: NCT01536691
Drug: ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
Study: NCT02808650
Drug: Prexasertib
Normalized name: Prexasertib
DrugBank: Prexasertib (DB12008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00506675
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily atropine (1%)
Study: NCT00506675
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once weekly atropine for 4 weeks, then no treatment
Study: NCT02787551
Drug: Insulin glargine/lixisenatide fixed ratio combination
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02787551
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02787551
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02787551
Drug: exenatide extended-release
Normalized name: Exenatide for Extended-Release Injectable Suspension
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02787551
Drug: albiglutide
Normalized name: Albiglutide
DrugBank: Albiglutide (DB09043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02787551
Drug: dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT03630367
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular injection 8 mg
Study: NCT03630367
Drug: L-Carnitine 1G/5mL Injection
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: slow intravenous injection
Study: NCT02276365
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02276365
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02350673
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
Study: NCT02350673
Drug: Cergutuzumab Amunaleukin
Normalized name: Cergutuzumab amunaleukin
DrugBank: Cergutuzumab amunaleukin (DB14874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
Study: NCT04556773
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T-DXd: administered as an IV infusion
Study: NCT00892658
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
Study: NCT01419639
Drug: Everolimus (RAD001) , Afinitor®
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
Study: NCT01878617
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ROA: IV
Study: NCT01878617
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ROA: IV
Study: NCT01878617
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ROA: Orally (PO)
Study: NCT04556773
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab: administered as an IV infusion
Study: NCT01677559
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00087061
Drug: gimatecan
Normalized name: Gimatecan
DrugBank: Gimatecan (DB06721)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01878617
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ROA: IV
Study: NCT01878617
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ROA: IV
Study: NCT04556773
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel: administered as an IV infusion
Study: NCT02314533
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
Study: NCT00440154
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00351546
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04807127
Drug: Immune checkpoint blockade
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI, administered as standard-of-care treatment
Study: NCT01497327
Drug: PSI-352938
Normalized name: PSI-352938
DrugBank: PSI-352938 (DB12896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSI-352938 300mg once daily (QD) for seven days
Study: NCT01497327
Drug: PSI-7977
Normalized name: psi-Norephedrine
DrugBank: Cathine (DB01486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSI-7977 400mg QD for seven days
Study: NCT04556773
Drug: Capivasertib
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib: administered orally
Study: NCT04556773
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole: administered orally
Study: NCT00002582
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002582
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002582
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00661674
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
Study: NCT04556773
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant: administered as an IM injection
Study: NCT01423149
Drug: Combretastatin A-4 Phosphate
Normalized name: Combretastatin A-4 phosphate
DrugBank: Combretastatin A4 (DB14680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
Study: NCT01541553
Drug: Ingenol metabute
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Field treatment with vehicle gel once daily for 3 consecutive days.
Study: NCT00661674
Drug: Hydroxyzine
Normalized name: Hydroxyzine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over 3 study visits, patients will receive one of the following treatment regimens:~* Placebo saline IV and sugar pill~* 0.75 mg Palonosetron IV and sugar pill~* 0.75 mg Palonosetron IV and 100 mg hydroxyzine PO
Study: NCT01218620
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01218620
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01218620
Drug: Midazolam Hydrochloride
Normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01218620
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01218620
Drug: Tolbutamide
Normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01218620
Drug: Dextromethorphan Hydrobromide
Normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03780894
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 1g of TXA together with FC and RBC
Study: NCT02634281
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
Study: NCT05490771
Drug: Copanlisib Hydrochloride
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04031027
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.
Study: NCT00424801
Drug: Lercanidipine
Normalized name: Lercanidipine
DrugBank: Lercanidipine (DB00528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual titration, max. dose 20 mg OD for 8 months
Study: NCT00424801
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individual titration, max. dose 160 mg OD for 8 months
Study: NCT01872689
Drug: Lebrikizumab
Normalized name: Lebrikizumab
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
Study: NCT01872689
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
Study: NCT00424801
Drug: Nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual titration, max. dose 20 mg BD for 8 months
Study: NCT00424801
Drug: Doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual titration, max. dose 4 mg OD for 8 months
Study: NCT00424801
Drug: Moxonidin
Normalized name: Moxonidina
DrugBank: Moxonidine (DB09242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
Study: NCT00424801
Drug: Pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
Study: NCT05115578
Drug: Midazolam 1 MG/ML Prefilled Syringe
Normalized name: midazolam 1 MG/ML Prefilled Syringe
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv
Study: NCT05115578
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group III Control
Study: NCT02939079
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Produced by Osveh ® Pharm Company in Iran